Caxton Associates (New York)’s Nektar Therapeutics NKTR Stock Holding History

Caxton Associates (New York)’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-17,312	Closed	-$587K	–	592
2022 Q4	$587K	Buy	17,312 +13,943	+414%	+$675K	0.04%	208
2022 Q3	$162K	Sell	3,369 -4,225	-56%	-$251K	0.02%	421
2022 Q2	$433K	Buy	+7,594	New	+$479K	0.04%	308
2019 Q4	–	Sell	-673	Closed	-$184K	–	507
2019 Q3	$184K	Buy	+673	New	+$247K	0.04%	352

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Caxton Associates (New York)'s NKTR Position: Q1 2023 in Review

Caxton Associates (New York) sold out of Nektar Therapeutics (NKTR) in Q1 2023, closing a stake of 17,312 shares — an estimated $587K sold.

Caxton Associates (New York) first reported a position in NKTR in Q3 2019 and held it in 4 quarters. The position peaked at $587K in Q4 2022. 194 funds tracked by Wall St. Rank hold NKTR as of Q1 2023.

Caxton Associates (New York) reported no remaining Nektar Therapeutics position as of Q1 2023 after selling out during the quarter.
Caxton Associates (New York) sold 17,312 Nektar Therapeutics shares in Q1 2023, an estimated $587K.
Caxton Associates (New York) first reported a position in Nektar Therapeutics in Q3 2019 and held it in 4 quarters.
Caxton Associates (New York)'s Nektar Therapeutics position peaked at $587K in Q4 2022.
194 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2023.

Based on Caxton Associates (New York)'s 13F filing for Q1 2023, filed 15 May 2023.